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It has become readily apparent in recent years that
a large number of drugs commonly used in the prac-
tice of medicine have the ability to cause impaired
water excretion [1]. In many cases, this effect is in
addition to and unrelated to the primary pharma-
cologic property of the drug. The impaired water
excretion resulting from use of the drug may cause
significant hyponatremia and water intoxication, re-
quiring termination of drug administration [I]. With
some drugs, the ability to impair water excretion has
been utilized therapeutically in the treatment of dia-
betes insipidus [2,3]. This report will review the drugs
presently known to be capable of causing impaired
water excretion in the mammalian kidney and, where
known, the mechanism by which each drug acts will
be discussed.
Mechanisms of impaired water excretion
Drugs can impair water excretion by means of
antidiuretic hormone (ADH) related mechanisms re-
sulting in increased water reabsorption by the distal
tubule and collecting duct of the kidney. This ADH-
mediated effect can be a consequence of drug-induced
stimulation of ADH release from the neurohypophy-
seal system or drug-induced potentiation of the ac-
tion of ADH on the renal medulla [4].
Impaired ability to excrete water may also be a
consequence of non-ADH-mediated alterations in
renal function. Thus, a marked decrease in the rate of
delivery of fluid to the distal tubule and collecting
duct, as may occur in response to a severe decrease in
renal blood flow and glomerular filtration rate, can
result in excretion of a moderately hypertonic urine
[5]. An increase in sodium reabsorption in the prox-
imal tubule will be accompanied by an increase in
water reabsorption with resultant decreased distal
delivery of fluid, which may be associated with
production of a hypertonic urine [6].
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In rare situations when water intake is sufficiently
high, the kidney may be unable to excrete the fluid
load rapidly enough so that excessive accumulation
of water can occur [7—9]. Some drugs may produce
dilutional hyponatremia by means of stimulation of
thirst with resultant excessive water ingestion [10].
Clinically, drugs which cause impaired water excre-
tion through an ADH-mediated mechanism may pro-
duce dilutional hyponatremia. Features suggestive of
this circumstance are weight gain without develop-
ment of edema and symptoms of water intoxica-
tion including lethargy, weakness, mental confusion,
convulsions and coma. In addition to hypona-
tremia, the blood urea nitrogen (BUN) concentra-
tion may be low and significant amounts of sodium
may be excreted in the urine, generally greater than
20 mEq/liter [11]. In order to attribute impaired
water excretion to a drug which a patient might be
taking, it is essential to exclude the presence of
congestive heart failure, renal failure, cirrhosis with
ascites, adrenal insufficiency and hyperthyroidism
since these disorders are often associated with im-
paired ability to excrete water.
Drugs capable of producing water retention
ADH analogues. A number of analogues of ADH
have been developed for clinical use which have po-
tent antidiuretic activity. These drugs have been used
primarily for the treatment of diabetes insipidus.
Among the early analogues developed was lysine
vasopressin (LVP), differing from human ADH by a
single amino acid substitution (lysine for arginine in
position 8). It has been effective in the treatment of
diabetes insipidus when administered as a nasal
spray, having a duration of activity of approximately
four to six hours [12]. More recently, l-deamino-8-D-
arginine vasopressin (DDAVP) has been synthesized.
This drug has marked antidiuretic activity with essen-
tially no pressor activity [13]. When administered as a
nasal spray to patients with diabetes insipidus, its
antidiuretic action is prolonged to 12 to 22 hr due to a
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decrease in rate of degradation and thus has been
effective even when given only at 12-hr intervals
[13—15]. Oxytocin, although possessing weak antidiu-
retic activity, can when administered in sufficiently
large amounts cause water retention. There are
several reports of water intoxication occurring in ob-
stetrical patients given large doses of oxytocin along
with fluid intravenously in an attempt to induce labor
[16,17].
Nicotine. Nicotine has long been recognized as
being able to produce an antidiuresis by stimulating
ADH release [18]. This pharmacologic property of
nicotine has been used in the development of a clini-
cal test for ADH releasing capacity [19]. Studies by
Husain et al have directly demonstrated a rise in
plasma ADH concentration in normal human sub-
jects following smoking of two cigarettes over a pe-
riod of five minutes [20]. Skowsky, Vawter and Swan
have shown that nicotine is capable of stimulating the
release of ADH from the isolated rat posterior pi-
tuitary in a perifusion system, indicating that the
effect of nicotine may be directly on the neurohy-
pophysis [21]. However, Cadnapaphornchai et a!, in
studying the action of nicotine on water excretion in
the dog, have concluded that the effect on ADH
release is indirect, being mediated by alteration in
cervical parasympathetic tone from baroreceptors of
the carotid sinus [22]. Recent experiments by Bisset et
al in the cat also support a neural reflex mechanism of
action. Injection of nicotine into the lateral or third
cerebral ventricle and into the subarachnoid space
produced release of ADH. Direct application of nico-
tine to the ventral surface of the medulla also resulted
in ADH release [23]. These data were interpreted as
indicating that there is a nicotine-sensitive synapse
between afferent fibers from baroreceptors and
stretch receptors and the central projection of these
fibers to the neurosecretory cells of the supraoptic
nucleus.
Narcotics. The acute administration of narcotics
has long been known to cause an antidiuresis. Dc
Bodo in 1944 showed that morphine administered to
dogs resulted in a decrease in urine flow along with
release of antidiuretic substance [24]. Subsequent
studies in the rat [25,26], dog [27] and man [26] have
confirmed these observations and indicate that mor-
phine causes release of ADH from the neurohy-
pophysis. Impairment of water excretion following
morphine administration during surgery is a well rec-
ognized clinical situation. Chronic administration of
morphine to the rat results in loss of the antidiuretic
effect and may actually lead to the onset of diuresis
[25,28,29],
Recently, several narcotic antagonists have been
observed to cause a diuresis when administered to the
rat [30] or to man [31,32]. Studies conducted in the
rat have clearly demonstrated that the narcotic antag-
onists have their diuretic effect by inhibition of ADH
release from the neurohypophysis [30]. These agents
may have therapeutic application in man in the treat-
ment of fluid-retaining states due to excessive hypo-
thalamic ADH release. One patient with chronic in-
appropriate ADH syndrome resulting from head
trauma was treated for eight days with the narcotic
antagonist oxilorphan (Fig. 1). During this time,
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Fig. 1. Response to treatment with the narcotic antagonist oxilor-
phan in a 26-yr-old man with chronic inappropriate A DH syndrome
due to head trauma. During eight days of drug treatment, there
was a progressive increase in urine volume with accompanying
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there was progressive increase in urinary volume and
progressive improvement in ability to excrete a water
load. After cessation of drug administration, hypo-
natremia no longer was present and the inappropriate
ADH syndrome remained improved [32]. Further
studies will be needed to allow clarification of the role
that these drugs may have in the treatment of im-
paired water excretion due to ADH excess.
Sulfonylureas. The antidiuretic action of chior-
propamide in patients with diabetes insipidus has
been recognized since 1966 [2,33—37]. The antidiure-
sis occurs not only if the patients drink fluids ad lib
but also if they are water loaded [2], thus eliminating
an effect through a decrease in thirst with associated
limitation of water intake. Chlorpropamide interferes
with the excretion of a water load by normal subjects
[2,4], and this effect of the drug is even greater in
water-loaded patients with diabetes insipidus [2]. The
antidiuretic action of chlorpropamide in patients
with diabetes insipidus has been shown to be additive
to that of carbamazepine [38] and of diuretics [39],
and it is reasonable to assume that there may be
additive actions with other water-retaining drugs.
There are numerous reports of patients with diabe-
tes mellitus who were treated with chlorpropamide
with subsequent development of water retention and
hyponatremia [40—44]. Chlorpropamide may even in-
duce symptomatic hyponatremia in patients with dia-
betes insipidus [45].
The occurrence of dilutional hyponatremia in pa-
tients with diabetes mellitus, who are treated with
chlorpropamide, seems to be more frequent when
there is an underlying tendency to retain fluids such
as occurs in congestive heart failure or cirrhosis of the
liver. While the incidence of hyponatremia in chlor-
propamide-treated patients with diabetes mellitus has
been estimated to be about 4% [42], the major reason
to be alert to the problem of water retention is that its
occurrence can be life-threatening. Nocturnal angina
pectoris, as a consequence of water retention, has
also been attributed to chlorpropamide [46].
The antidiuresis of chlorpropamide appears to be
ADH-mediated. Thus, it occurs without a fall in gb-
merular filtration rate or osmolal clearance [2]. In
addition, the antidiuretic action of chborpropamide in
patients with diabetes insipidus is proportionate to
their ability to release ADH and concentrate the
urine in response to dehydration [2]. Additional evi-
dence for the role of endogenous ADH is derived
from the observations that ethanol and diphenyl-
hydantoin, both of which are inhibitors of ADH
release, overcome the antidiuretic action of chlor-
propamide [2,47]. Chlorpropamide has no antidi-
uretic effect in patients with nephrogenic diabetes
insipidus [33,48,49], in the Brattleboro rat [50] or on
the toad bladder in vitro [51]. Chlorpropamide has
been shown to augment the action of ADH on the
hydroosmotic movement of water in the toad bladder
[51], in the Brattleboro rat [50] and in patients with
diabetes insipidus [4,52]. The mechanism of augmen-
tation of the action of ADH is related to an increased
activation of renal medullary adenylate cyclase by
ADH in the presence of chlorpropamide [53]. Renal
medullary slices taken from rats treated with chlor-
propamide have a greater cyclic AMP and adenylate
cyclase response to ADH which is added in vitro [54].
In addition to the peripheral augmentation of ADH,
chborpropamide may also stimulate ADH release
since it overcomes the inhibition of ADH release
which normally occurs with water loading. Thus,
urinary ADH concentrations are higher in water-
loaded normal subjects treated with chlorpropamide
than in the same subjects water-loaded without drug
treatment [4]. A central mode of action of chior-
propamide is further supported by the observation
that the drug can restore normal drinking behavior in
patients with hypodipsia [55].
Tolbutamide is ineffective in the treatment of pa-
tients with diabetes insipidus. The oral administra-
tion of tolbutamide to normal man also does not
interfere with the excretion of water (unpublished
observation). Although tolbutamide is capable of
causing water retention in some patients with diabe-
tes mellitus [40,56], probably through the same mech-
anisms as chlorpropamide, the occurrence of this
problem is uncommon and cannot be considered to
be a clinically significant action of the drug.
Several sulfonylurea agents (glyburide, tolazamide
and acetohexamide) have diuretic actions in hydrated
normal subjects [57]. Glyburide enhances water ex-
cretion in patients with diabetes insipidus [58,59] and
diabetes mellitus [57]. Preliminary observations in
our laboratory indicated that in hyponatremic, ede-
matous, cirrhotic patients, tolazamide increases the
maximum urine flow rate and free water excretion,
and decreases the minimum urine osmolality attained
after a single 20 mI/kg water load.
The diuretic action of glyburide, and presumably
of the other diuretic sulfonylureas, occurs without
inhibition of the release or peripheral action of ADH
[59,60]. Experimental studies indicate that the most
probable explanation for the diuretic action is inhibi-
tion of tubular reabsorption which then results in
increased free water excretion. Since glyburide and
the other sulfonylureas in this group act as diuretics,
this property should be considered in the selection of
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hypoglycemic agents for treatment of patients with
diabetes mellitus, particularly when there is an under-
lying water-retaining tendency.
Biguanides. The biguanides, phenformin and met-
formin, have been reported to have antidiuretic ef-
fects in patients with hypothalamic diabetes insipidus
[61,62]. There is no evidence that these drugs have
any direct antidiuretic action and it has been sug-
gested that they may act by potentiating the action of
ADH [62]. In opposition to this view is the report by
Villamor et al who observed that phenformin had an
antidiuretic effect in two patients with nephrogenic
diabetes insipidus [63]. Studies with normal subjects
conducted in our laboratory have shown no evidence
of impaired water excretion following administra-
tion of phenformin. Recently, De Troyer, Davis and
Demanet have reported a patient with diabetes mel-
litus who developed hyponatremia while receiving
phenformin [64]. However, the patient was also re-
ceiving polythiazide and it therefore cannot be clearly
assumed that the hyponatremia was due to phenfor-
mm.
Clofibrate. Clofibrate exerts an antidiuretic action
in many patients with diabetes insipidus who have
some releasable ADH [65—67], and inhibits the excre-
tion of a water load in normal subjects [3]. The
antidiuretic action of clofibrate, like that of chior-
propamide, is more effective in patients with diabetes
insipidus than in normal subjects [2,3]. Although
some patients with hyperlipidemia who are treated
with clofibrate are reported to gain weight, there are
no documented cases of a dilutional hyponatremic
state resulting from treatment with this hypolipi-
demic drug.
The antidiuretic action of clofibrate appears to be
ADH-mediated. Like ADH, its effect is overcome by
ethanol [3]. It is ineffective in patients with nephro-
genic diabetes insipidus [68]. Clofibrate appears to
have no intrinsic antidiuretic action of its own [3,67]
and there is no evidence that it potentiates the pe-
ripheral action of ADH [3,69]. The drug appears to
act by releasing endogenous ADH from the neurohy-
pophysis since clofibrate increases the amount of
ADH in the urine of water-loaded man [3].
A structurally related hypolipidemic agent, halofe-
nate, exerted an antidiuretic action in one patient
with diabetes insipidus [70].
Tricyclics. Carbamazepine (Tegretol), used as an
anticonvulsant and in the treatment of tic doulou-
reux, has been known since 1966 to be effective in the
treatment of diabetes insipidus [71—73]. Water in-
toxication resembling the syndrome of inappropriate
secretion of ADH (SIADH) has been observed in a
patient with primary polydipsia who was treated with
carbamazepine [74]. Radó pointed out the similar-
ity between carbamazepine-induced and chiorpropa-
mide-induced dilutional hyponatremia, and demon-
strated that these two drugs have additive antidiuretic
actions in patients with partial central diabetes insip-
idus [38].
The antidiuretic action of carbamazepine appears
to be mediated through endogenous ADH [75]. Like
ADH, its effect is overcome by ethanol [76]. The drug
increases plasma ADH concentrations in patients
with diabetes insipidus [77,78]. Carbamazepine has
no intrinsic antidiuretic action in the Brattleboro rat
[65,75] or on movement of water across the toad
bladder [65], and does not augment the antidiuretic
action of submaximal doses of ADH in experimental
animals [65,69,75]. Patients with nephrogenic diabe-
tes insipidus do not concentrate urine after carba-
mazepine administration [68,75].
Hyponatremia has been reported in patients treated
with amitriptyline (Elavil), thiothixene (Navane)
and fluphenazine [79—81]. There is no available in-
formation on the mechanism involved in the water
retention observed with these drugs.
Thioridazine (Mellaril) may cause water intoxi-
cation by stimulating excessive water intake. Even
though there is a normal urinary diluting capacity,
hyponatremia may result from the inability of the
normal kidney to excrete the excessive fluid load [10].
The dryness of the mouth caused by the anticholiner-
gic action of this and other tricyclic agents [82] may
aggravate tendencies toward compulsive water drink-
ing. It is possible also that thioridazine may stimulate
directly the hypothalamic thirst center.
Antineoplastic agents. Vincristine is widely used in
the treatment of leukemias, lymphomas and certain
solid tumors. The description of hyponatremia in a
patient treated with vincristine in 1966 [83] has been
followed by other reports of severe SIADH in chil-
dren and in adults treated with the drug [84—87]. The
syndrome is usually recognized one or two weeks
after the onset of treatment and usually subsides
about two weeks later. Elevated plasma concentra-
tions of ADH have been reported in patients with this
syndrome [88], and urinary ADH has been increased
after each treatment with vincristine in a child with
leukemia [89]. A neurotoxic mechanism for ADH
release is supported by the observation that the addi-
tion of vincristine to the incubated rat neurohy-
pophysis causes definite microscopic changes, includ-
ing precipitation of microtubules and deposition of
crystals [90].
Cyclophosphamide, a potent antineoplastic and
immunosuppressive agent, has produced an ADH-
like antidiuresis when injected intravenously into
100 Miller and Moses
water-loaded patients [91]. Ethanol may decrease
this antidiuretic action [91], The injection of cy-
clophosphamide into normally hydrated patients
caused an antidiuresis beginning in 4 to 12 hr and
lasting as long as 20 hr [91]. The antidiuresis was
related to the urinary excretion of active alkylating
metabolites of the drug [92]. Cytosine arabinoside
did not cause water retention [92]. These observa-
tions in man are in contrast to those of Zedeck,
Mellett and Cafruny, who produced a diuresis in
animals with cyclophosphamide [931. The water-re-
taining properties of cyclophosphamide and vincris-
tine are particularly important because patients so
treated are frequently hydrated to prevent the forma-
tion of uric acid stones and drug-related cystitis.
Analgesics. Acetaminophen has been reported to
be an effective agent in the treatment of diabetes
insipidus [94], but there is no information on the
effect of this drug in patients with the nephrogenic
form of the disorder. Concentration of urine in
patients with diabetes insipidus occurs without any
appreciable change in renal hemodynamics [94].
There is no evidence for an intrinsic ADH-like action
of acetaminophen [53], but acetaminophen has been
shown to enhance the sensitivity of the toad bladder
to the action of ADH [95]. We are not aware of any
reported instances of dilutional hyponatreniia occur-
ring as a consequence of use of this drug.
In hydrated subjects aspirin, indomethacin and
ibuprofen exert antidiuretic actions ([96] and unpub-
lished observations). Indomethacin augments the an-
tidiuretic action of infused ADH in hydrated normal
subjects and patients with diabetes insipidus [97] and
aspirin enhances the hydroosmotic effect of ADH on
the toad bladder [98]. These observations are con-
sistent with the possibility that inhibition of renal
prostaglandin synthesis by these drugs may result
in an antidiuresis.
Diuretics. The ability of thiazide diuretic agents to
cause water retention in patients with both hypotha-
lamic and nephrogenic diabetes insipidus has been
known since 1959 [991. More recently, severe dilu-
tional hyponatremia has been described as a con-
sequence of diuretic therapy [39,100]. In addition to
thiazides, other natriuretic drugs, including furose-
mide, can cause dilutional hyponatremia similar to
that seen in inappropriate ADH syndrome [39]. The
mechanism of antidiuretic effect of these drugs may
in part be due to reduction in glomerular filtration
rate and enhanced reabsorption of sodium and water
proximal to the distal diluting sites [6]. In addition,
diuretic-induced potassium depletion has been sug-
gested to enhance the effect of extracellular fluid vol-
ume contraction to stimulate ADH release through
activation of volume receptors [39]. There is evidence
suggesting a synergistic action between diuretics and
chiorpropamide since the combination has been re-
ported to induce water retention in a situation in
which neither drug alone had this effect [391.
Diazoxide, a thiazide derivative, is capable of caus-
ing sodium retention [101]. The drug decreases free
water clearance in patients with both hypothalamic
and nephrogenic diabetes insipidus as well as in nor-
mal subjects, without change in the glomerular filtra-
tion rate [102]. Diazoxide may act by increasing
proximal tubular reabsorption of water and sodium
due to its peripheral vasodilator action [102]. There
are no reports of dilutional hyponatremia due to
diazoxide, perhaps because the drug is usually used
acutely for the treatment of severe hypertension.
Conclusions
It is evident from the above that administration of
a wide variety of drugs may result in the development
of impaired water excretion. In some cases, the drugs
have a direct ADH-like effect on the kidney. Other
drugs act through an ADH-mediated mechanism ei-
ther by causing the release of ADH from the neu-
rohypophyseal system or by potentiating the action
of small amounts of ADH on the kidney tubule.
Some drugs appear capable of impairing water excre-
tion primarily by alteration of renal hemodynamics,
i.e., decrease in renal blood flow and glomerular fil-
tration rate or enhanced proximal reabsorption of
sodium and water. In a few instances, a drug may
stimulate excessive fluid intake with resultant in-
ability of the kidney to excrete the fluid load with
sufficient rapidity. It is to be expected that drugs
other than those discussed in this review will be found
to have significant effects on water excretion.
The clinician must be aware of the possibility that
drugs or combinations of drugs may cause impaired
water excretion, in some instances, the water reten-
tion resulting- from drug use may be sufficient to
cause severe symptomatic hyponatremia and water
intoxication. Awareness of the possible relationship
to drug usage and the mechanism of drug action will
allow appropriate therapy to be promptly instituted.
The ability of a variety of drugs to cause impaired
water excretion has been successfully utilized in the
development of improved methods for the treatment
of diabetes insipidus. Thus, for the patient with hy-
pothalamic diabetes insipidus, there is a choice
among easily administered ADH analogues, agents
capable of stimulating release of small amounts of
remaining endogenous ADH or drugs capable of po-
tentiating the renal action of otherwise ineffective
amounts of circulating ADH. In some instances, a
Drug-induced impairment of water excretion 101
combination of drugs having several different mecha-
nisms of action will result in the establishment of a
satisfactory therapeutic regimen for a patient who
previously responded poorly to individual drugs. Al-
though the current drug treatment of patients with
nephrogenic diabetes insipidus is far from satisfac-
tory, it can be assumed that as the biochemical de-
fects responsible for this disorder become better un-
derstood, it will be possible to develop drugs capable
of specific correction of the defects.
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